Teva, Lundbeck halt work on oral MS drug

03/21/2006 | Globes (Israel)

Israel's Teva and Danish drugmaker H. Lundbeck A/S announced they would halt development of an oral version of Teva's injectable multiple sclerosis drug Copaxone, saying trial results were not as significant as those for the existing drug. However, Teva plans to continue efforts with Sweden's Active Biotech to develop and market another oral therapy for which trials were conducted in 2005.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA